Actinium Pharmaceuticals (ATNM) Amortization of Deferred Charges (2012 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Amortization of Deferred Charges of $191000.0 for Q1 2026, up 20.89% year-over-year from $158000.0 in Q1 2025, and up 20.89% quarter-over-quarter from $158000.0 in Q1 2025.
Actinium Pharmaceuticals (ATNM) Amortization of Deferred Charges (2012 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Amortization of Deferred Charges for 3 consecutive years, with $191000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 20.89% year-over-year to $191000.0; the TTM figure through Mar 2026 stood at $641704.0 (up 22.54% YoY), while the FY2025 annual figure was $648000.0, up 5.54% from the prior year.
- Amortization of Deferred Charges grew to $191000.0 in Q1 2026 per ATNM's latest filing, from $158000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $191000.0 in Q1 2026 and bottomed at $158000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 191,000.00 |
| Mar 31, 2026 | 191,000.00 |
| Mar 31, 2025 | 158,000.00 |
| Mar 31, 2025 | 158,000.00 |
| Sep 30, 2012 | 219,725.00 |
| Sep 30, 2012 | 219,725.00 |
| Jun 30, 2012 | 72,979.00 |
| Jun 30, 2012 | 72,979.00 |
| Mar 31, 2012 | 72,972.00 |
| Mar 31, 2012 | 72,972.00 |